Literature DB >> 16532471

LRRK2 expression linked to dopamine-innervated areas.

Dagmar Galter1, Marie Westerlund, Andrea Carmine, Eva Lindqvist, Olof Sydow, Lars Olson.   

Abstract

OBJECTIVE: Leucine-rich repeat kinase 2 (LRRK2) has been linked to Parkinson's disease. Our study explores the expression of LRRK2 in human and rodent brain tissue.
METHODS: We analyzed LRRK2 gene activity at the cellular level using in situ hybridization.
RESULTS: We found a high and strikingly specific expression of LRRK2 mRNA in rodent striatum and parts of cortex and no signals in dopamine neurons. In human tissue, LRRK2 mRNA was found in the corresponding brain areas caudatus and putamen at lower levels and dopamine neurons were also devoid of LRRK2 mRNA. Expression levels in striatal tissue did not differ between Parkinson's disease patients and control subjects.
INTERPRETATION: Unlike all other genes so far linked to Parkinson's disease, our results demonstrate that LRRK2 expression is particularly high in brain dopaminoceptive areas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532471     DOI: 10.1002/ana.20808

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  72 in total

1.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

Review 2.  Mitochondrial medicine for aging and neurodegenerative diseases.

Authors:  P Hemachandra Reddy
Journal:  Neuromolecular Med       Date:  2008-06-20       Impact factor: 3.843

3.  Cell type-specific expression analysis to identify putative cellular mechanisms for neurogenetic disorders.

Authors:  Xiaoxiao Xu; Alan B Wells; David R O'Brien; Arye Nehorai; Joseph D Dougherty
Journal:  J Neurosci       Date:  2014-01-22       Impact factor: 6.167

Review 4.  Mechanisms of LRRK2-mediated neurodegeneration.

Authors:  Elpida Tsika; Darren J Moore
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

5.  Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents.

Authors:  Andrew B West; Rita M Cowell; João P L Daher; Mark S Moehle; Kelly M Hinkle; Heather L Melrose; David G Standaert; Laura A Volpicelli-Daley
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

6.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

Review 7.  Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Authors:  Iakov N Rudenko; Mark R Cookson
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

8.  Gene expression profiles of mouse striatum in control and maneb + paraquat-induced Parkinson's disease phenotype: validation of differentially expressed energy metabolizing transcripts.

Authors:  Suman Patel; Kavita Singh; Seema Singh; Mahendra Pratap Singh
Journal:  Mol Biotechnol       Date:  2008-04-02       Impact factor: 2.695

9.  Emerging role of LRRK2 in human neural progenitor cell cycle progression, survival and differentiation.

Authors:  Javorina Milosevic; Sigrid C Schwarz; Vera Ogunlade; Anne K Meyer; Alexander Storch; Johannes Schwarz
Journal:  Mol Neurodegener       Date:  2009-06-15       Impact factor: 14.195

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.